- 4-Week # shares sold: 12,468
- 12-Week # shares sold: 13,050
- 24-Week # shares sold: 13,197
The animal health industry looks poised for growth, analysts say, and Idexx Laboratories IDXX stands to benefit.
Cepheid's (CPHD) stock rating was cut to 'neutral' at Baird on Monday morning.
Barclays hiked Cepheid's (CPHD) stock price target to $52 on Wednesday after Danaher (DHR) agreed to buy the company for $4 billion yesterday.
Potential targets of the medical device and diagnostics giant might request stricter parameters when structuring a deal, company followers say.
Mergers and high-growth stocks are making the market better and better, Cramer says.